“…There is also a lack of research evidence that more than one antipsychotic agent is better than one for either short-or long-term treatment, even though antipsychotic combinations ("polytherapy," preferred to the widely employed term "polypharmacy") are commonly used empirically, probably largely in response to typically limited bene fi ts in chronic and disabling illnesses that are dif fi cult to treat, and perhaps owing to clinical sensitivity to the obligation to limit risks commonly associated with unusually high doses of individual drugs [ 35,37,60,67 ] . Polytherapy has rarely been tested for added bene fi ts or safety, but can be expected to add to overall patient side-effect burden, complexity of regimens, risk of nonadherence, and costs, whether or not clinically signi fi cant drug-interactions or major adverse effects increase [ 37 ] .…”